Home
CSCI
CSCI News

Latest COSCIENS BIOPHARMA INC (CSCI) News on April 24, 2025

COSCIENS Biopharma Inc. Appoints Global Consumer Products and Biosciences Executive, Anna Biehn as Chief Executive Officer

GlobeNewswire

10 days ago

COSCIENS Biopharma Inc. Appoints Global Consumer Products and Biosciences Executive, Anna Biehn as Chief Executive Officer

COSCIENS Biopharma Full Year 2024 Earnings: US$5.93 loss per share (vs US$13.64 loss in FY 2023)

Simply Wall St.

12 days ago

COSCIENS Biopharma Full Year 2024 Earnings: US$5.93 loss per share (vs US$13.64 loss in FY 2023)

COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

GlobeNewswire

15 days ago

COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order

GlobeNewswire

23 days ago

COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order

COSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting Documents

Newsfile

a month ago

COSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting Documents

COSCIENS Biopharma Inc. Announces Successful Phase 1 Results Supporting Initiation of Phase 2a Clinical Efficacy Trial with Avenanthramides as a Potential Anti-Inflammatory Product

GlobeNewswire

a month ago

COSCIENS Biopharma Inc. Announces Successful Phase 1 Results Supporting Initiation of Phase 2a Clinical Efficacy Trial with Avenanthramides as a Potential Anti-Inflammatory Product

COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization

GlobeNewswire

4 months ago

COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization

COSCIENS Biopharma Third Quarter 2024 Earnings: US$1.85 loss per share (vs US$3.41 loss in 3Q 2023)

Simply Wall St.

5 months ago

COSCIENS Biopharma Third Quarter 2024 Earnings: US$1.85 loss per share (vs US$3.41 loss in 3Q 2023)

COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs

GlobeNewswire

5 months ago

COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs

COSCIENS Biopharma Announces Change to Board of Directors

GlobeNewswire

7 months ago

COSCIENS Biopharma Announces Change to Board of Directors

COSCIENS Biopharma Announces Appointment of Pierre Labbé as Director

GlobeNewswire

7 months ago

COSCIENS Biopharma Announces Appointment of Pierre Labbé as Director

COSCIENS Biopharma Inc. Provides Updates on Merger Integration, Management Succession Plans and Ongoing Development Programs

GlobeNewswire

7 months ago

COSCIENS Biopharma Inc. Provides Updates on Merger Integration, Management Succession Plans and Ongoing Development Programs

COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

GlobeNewswire

8 months ago

COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results

GlobeNewswire

8 months ago

COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results

Share on Social Networks: